0001104659-23-079123.txt : 20230707
0001104659-23-079123.hdr.sgml : 20230707
20230707161119
ACCESSION NUMBER: 0001104659-23-079123
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20230707
DATE AS OF CHANGE: 20230707
EFFECTIVENESS DATE: 20230707
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001173281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465622433
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-486254
FILM NUMBER: 231076908
BUSINESS ADDRESS:
STREET 1: 350 TECHNOLOGY DRIVE
CITY: PITTSBURGH
STATE: PA
ZIP: 15219
BUSINESS PHONE: 412-763-3350
MAIL ADDRESS:
STREET 1: 350 TECHNOLOGY DRIVE
CITY: PITTSBURGH
STATE: PA
ZIP: 15219
FORMER COMPANY:
FORMER CONFORMED NAME: Ohr Pharmaceutical Inc
DATE OF NAME CHANGE: 20090819
FORMER COMPANY:
FORMER CONFORMED NAME: BBM HOLDINGS, INC.
DATE OF NAME CHANGE: 20070402
FORMER COMPANY:
FORMER CONFORMED NAME: PRIME RESOURCE INC
DATE OF NAME CHANGE: 20020513
D
1
primary_doc.xml
X0708
D
LIVE
0001173281
NeuBase Therapeutics, Inc.
350 TECHNOLOGY DRIVE
PITTSBURGH
PA
PENNSYLVANIA
15219
412-763-3350
DELAWARE
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical Inc
BBM HOLDINGS, INC.
PRIME RESOURCE INC
Corporation
true
Dietrich
Stephan
350 Technology Drive
Pittsburgh
PA
PENNSYLVANIA
15219
Executive Officer
Director
Todd
Branning
350 Technology Drive
Pittsburgh
PA
PENNSYLVANIA
15219
Executive Officer
Dov
Goldstein
350 Technology Drive
Pittsburgh
PA
PENNSYLVANIA
15219
Director
Eric
Richman
350 Technology Drive
Pittsburgh
PA
PENNSYLVANIA
15219
Director
Franklyn
Prendergast
350 Technology Drive
Pittsburgh
PA
PENNSYLVANIA
15219
Director
Gerald
McDougall
350 Technology Drive
Pittsburgh
PA
PENNSYLVANIA
15219
Director
Biotechnology
No Revenues
- 06b
false
2023-06-28
false
true
true
true
false
0
H.C. Wainwright & Co., LLC
375
None
None
430 PARK AVENUE
3RD FLOOR
NEW YORK
NY
NEW YORK
10022
NY
NEW YORK
false
5000002
5000002
0
The total offering amount herein reflects aggregate purchase price received by the Company in connection with the sale by the Company of the securities to the investor in a concurrent registered direct offering and the aforementioned private placements.
false
1
482389
0
The placement agent received $482,389.00 and warrants to purchase up to 136,187 shares of common stock exercisable at $3.2125 per share. Upon exercise of certain warrants, the Company will pay the placement agent an additional cash fee and warrants.
0
false
NeuBase Therapeutics, Inc.
/s/ Todd Branning
Todd Branning
Chief Financial Officer
2023-07-07